One-year treatment with standard and sustained-release levodopa: Appropriate long-term treatment of restless legs syndrome?

Movement Disorders

Volumn 18, Issue 10, 2003, Pages 1184-1189

  Trenkwalder, Claudia ^a,f   Seidel, Victor Collado ^a,f   Kazenwadel, Jörg ^c   Wetter, Thomas C ^a,f   Oertel, Wolfgang ^b   Selzer, Roland ^d   Kohnen, Ralf ^e  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d ROCHE INNOVATION CENTER MUNICH   (Germany)

^e Biometrics GmbH   (Germany)

^f UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Augmentation; Benserazide; Extension; Levodopa; Quality of life; Restless legs syndrome; Sleep; Therapy; Time shift

Indexed keywords

ANTIDEPRESSANT AGENT; BENSERAZIDE PLUS LEVODOPA; BENZODIAZEPINE; CARBIDOPA; ESTROGEN; GINKGO BILOBA EXTRACT; LEVODOPA; NEUROLEPTIC AGENT; OPIATE; SEDATIVE AGENT; THIOCTIC ACID; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; ARTICLE; BRADYCARDIA; CLINICAL ARTICLE; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; FEMALE; HUMAN; LIFE SATISFACTION; MALE; MEDICAL RECORD; PATIENT SATISFACTION; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RESTLESS LEGS SYNDROME; SICK SINUS SYNDROME; SLEEP; SLEEP TIME; SUSTAINED RELEASE PREPARATION; TREATMENT OUTCOME; XEROSTOMIA;

ADULT; AGED; ANTIPARKINSON AGENTS; BENSERAZIDE; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LEVODOPA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; RESTLESS LEGS SYNDROME; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 0242288097     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10503     Document Type: Article

References (19)

1. Chesson AL Jr, Wise M, Davila D, Johnson S, Littner M, Anderson WM, Hartse K, Rafecas J. Practice parameters for the treatment of restless legs syndrome and periodic limb movement disorder. An American Academy of Sleep Medicine Report. Standards of Practice committee of the American Academy of Sleep Medicine. Sleep 1999;22:961-968.
2. Hening W, Allen R, Earley C, Kushida C, Picchietti D, Silber M. The treatment of restless legs syndrome and periodic limb movement disorder. An American Academy of Sleep Medicine Review. Sleep 1999;22:970-999.
3. Brodeur C, Montplaisir J, Godbout R, Marinier R. Treatment of restless legs syndrome and periodic movements during sleep with L-dopa: a double-blind, controlled study. Neurology 1988; 38:1845-1848.
4. Trenkwalder C, Stiasny K, Pollmächer T, Kazenwadel J, Kohnen R, Krüger HP, Kuenzel M, Ramm S, Oertel WH. Effective L-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind crossover trial. Sleep 1995;18:681-688.
5. Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 1996;19:205-213.
6. Guilleminault C, Cetel M, Philip P. Dopaminergic treatment of restless legs and rebound phenomenon. Neurology 1993;43:445.
7. Collado-Seidel V, Kazenwadel J, Wetter TC, Kohnen R, Winkelmann J, Selzer R, Oertel WH, Trenkwalder C. Combination of regular and sustained release L-dopa/benserazide in the therapy of restless legs syndrome: a double-blind, crossover trial using actigraphy. Neurology 1999;52:285-290.
8. Walters AS, for the International Restless Legs Syndrome Study Group. Toward a better definition of the restless legs syndrome. Mov Disord 1995;10:634-642.
9. Guy W, Bonato RR, editors. Manual for the EDCEU Assessment Battery, 2nd revised ed. Chevy Chase: National Institute for Mental Health; 1976. p 12-1-12-6.
10. Kramer C, von Kerekjarto M, Leplow B, Krasemann EO. Measuring quality of life in weekly assessment of the disease course in myocardial infarct patients: initial results of methodology [in German]. Psychother Psychosom Med Psychol 1990;40:409-416.
11. Walker SL, Fine A, Kryger MH. 1996. L-dopa/carbidopa for nocturnal movement disorders in uremia. Sleep 1996;19:214-218.
12. Benes H, Kurella B, Kummer J, Kazenwadel J, Selzer R, Kohnen R. Rapid onset of action of levodopa in restless legs syndrome: a double-blind, randomised, multi-center, crossover trial. Sleep 1999;22:1073-1081.
13. von Scheele C, Kempi V. Long-term effect of dopaminergic drugs in restless legs. A 2-year follow-up. Arch Neurol 1990;47:1223-1224.
14. Becker PM, Jamieson AO, Brown WD. Dopaminergic agents in restless legs syndrome and periodic limb movements of sleep: response and complications of extended treatment in 49 cases. Sleep 1993;16:713-716.
15. Stiasny K, Wetter TC, Winkelmann J, Brandenburg U, Penzel T, Rubin M, Hundemer HP, Oertel WH, Trenkwalder C. Long-term effects in the treatment of restless legs syndrome. Neurology 2001;56:1399-1402.
16. Montplaisir J, Denesle R, Petit D. Pramipexole in the treatment of restless legs syndrome: a follow-up study. Eur J Neurol 2000; 7(Suppl. 1):27-31.
17. Ferini-Strambi L, Oldani A, Castronovo V, Zucconi M. RLS augmentation and pramipexole long-term treatment [abstract]. Neurology 2001;56(Suppl. 3):A20.
18. Hening WA, Walters A, Kavey N, Gidro-Frank S, Coté L, Fahn S. Dyskinesias while awake and periodic movements in sleep in restless legs syndrome: treatment with opioids. Neurology 1986; 36:1363-1366.
19. Crevoisier C, Hoevels B, Zurcher G, Da Prada M. 1987. Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. Eur Neurol 1987;27(Suppl. 1):36-46.